A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Part of paid clinical trials in Silver Spring, Maryland.
- Sponsor
- AstraZeneca
- Study ID
- NCT04765059
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 130 Years
- Healthy Volunteers
- Not accepted
Interventions
- Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin — DRUGRandomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
- Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin — DRUGRandomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
Study Details
The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following first-line osimertinib treatment.
Key Dates
- Start date
- Sep 12, 2021
- Status verified
- Mar 2026
- Primary completion
- Oct 28, 2024
- Completion
- Jun 2, 2027
Study Design
- Enrollment
- 98 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment Arm AAll randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m\^2) (with pre-treatment) plus either cisplatin (75 mg/m\^2) or carboplatin (\[AUC\] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m\^2) on Day 1 of 21-day cycles
- Placebo Comparator: Treatment Arm BAll randomized patients will receive placebo QD with pemetrexed (500 mg/m\^2) (with pre-treatment) plus either cisplatin (75 mg/m\^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m\^2) on Day 1 of 21-day cycles
Primary Outcome Measure
Progression Free Survival (PFS) [ Time Frame: From date of first dose (Day 1) until date of progression at local site or death due to any cause or data cut-off date whichever occurred first (up to 3 years 1 month) ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Silver Spring | Maryland | 20910 | - |
| Research Site | Boston | Massachusetts | 02114 | - |
Related coverage on Hipa.ai
- Trial results posted: NCT04765059Osimertinib · Jan 13, 2026 · ClinicalTrials.gov
Find similar trials in Silver Spring, MD
By condition
By specialty
By research site
Related Studies
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPHASE3 · Recruiting · University of Texas Southwestern Medical Center · La Jolla, California
- Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland